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Abstract: The objective of this review is to provide information on cardiovascular risk   following 
androgen-deprivation therapy (ADT) in prostate cancer patients and to suggest potential 
  prevention and management strategies. Androgen deprivation therapy can cause peripheral 
insulin resistance, increase fat mass and low-density lipoprotein cholesterol, and induce type 
2 diabetes. While recent studies have reported an association in patients with prostate cancer 
between ADT and increased risk of cardiovascular events, other studies have not detected the 
association. However, at this time, it is plausible that ADT could increase cardiovascular risk 
because of the adverse effect of ADT on risk factors for cardiovascular disease. It is advisable 
that prostate cancer patients in whom ADT is initiated be referred to their physician, who will 
carefully monitor them for potential metabolic effects. Therefore, physicians should be informed 
about these potential side effects. This especially applies to men aged .65 years and those with 
pre-existing cardiovascular comorbidities. Adopting a healthy lifestyle including a   balanced 
diet and regular physical activity is recommended. Patients with cardiovascular disease should 
receive appropriate preventive therapies, including lipid-lowering,   antihypertensive, glucose-
lowering, and antiplatelet therapy. ADT should preferably not be unnecessarily administered 
to prostate cancer patients with pre-existing cardiovascular disease, certainly not to those in 
whom the risk of prostate cancer-specific mortality is low. The physician should carefully weigh 
the potential benefits of ADT against the possible risks in individual patients with prostate 
cancer.
Keywords: androgen-deprivation therapy, cardiovascular disease, complications, prostate 
cancer
Introduction
The standard treatment for locally advanced and metastatic prostate cancer is 
androgen-deprivation therapy (ADT), which can be achieved by means of surgical 
castration (orchiectomy) or the use of gonadotropin-releasing hormone agonists or 
antagonists.
Recent epidemiological data indicate that ADT is increasingly being used in 
asymptomatic patients with early-stage disease, a setting in which benefits are lacking.1 
Patients are increasingly exposed to long-term ADT, and may take gonadotropin-
releasing hormone agonists for more than 10 years. However, ADT is accompanied by 
a number of adverse effects (Table 1).2 Concerns have been raised particularly about 
metabolic and cardiovascular side effects of ADT because of their impact on morbidity 
and mortality in men with prostate cancer. The purpose of this review is to provide Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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information on cardiovascular risk following ADT in   prostate 
cancer patients and to suggest potential prevention and 
  management strategies.
Methods
Data for this review were identified on Medline using the 
search terms “prostate neoplasms” (MeSH), “gonadotropin-
releasing hormone” (MeSH), “androgen antagonists” 
(MeSH), and “cardiovascular diseases” (MeSH major 
topic). From the references obtained, selection was made 
based on the clinical relevance and importance of the article. 
  Subsequent references were identified from the reference 
lists of retrieved articles. The search was limited to papers 
published in English between 2001 and 2010.
Metabolic side effects of ADT
Several mechanisms may contribute to cardiovascular 
toxicity. Prospective clinical studies have demonstrated 
that ADT causes dramatic changes in the patient’s body 
mass composition and induces peripheral resistance to 
insulin that can induce or precipitate type 2 diabetes and 
dyslipidemia.3–8 ADT causes a very morbid combination of 
muscular atrophy (decreased lean mass) and an increase in 
fatty deposits, a situation known as “sarcopenic obesity”.9 
Sarcopenic obesity is associated with several typical 
features of the metabolic syndrome, such as increased 
subcutaneous fat, increased high-density lipoprotein cho-
lesterol, and increased levels of adiponectin.10 According 
to the National Cholesterol   Education Program’s Adult 
Treatment Panel III guidelines, a man is considered to 
have metabolic syndrome if he meets three of the criteria 
shown in Table 2.11 A cross-sectional study showed that 
nearly 80% of prostate cancer patients on ADT for at 
least 1 year had a waist circumference $102 cm and 55% 
of these patients have metabolic syndrome, predisposing 
them to higher cardiovascular risk. Among the components 
of metabolic syndrome, ADT-treated men had a higher 
prevalence of abdominal obesity and hyperglycemia. 
They also had elevated triglycerides compared with 
controls.12 Prospective studies have shown that some of the 
ADT-associated changes are different from the classical 
metabolic syndrome changes (Table 3). ADT increases 
subcutaneous rather than visceral fat.6 Additionally, ADT 
increases rather than decreases high-density lipoprotein 
cholesterol and does not change waist-to-hip ratio. Finally, 
ADT is associated with increased serum adiponectin 
levels and unchanged C-reactive protein levels, while 
the conventional metabolic syndrome is characterized by 
low levels of adiponectin and increased C-reactive pro-
tein. ADT-associated metabolic changes may lead to an 
increased risk of cardiovascular morbidity and mortality. 
An increase in arterial stiffness may also contribute to 
the association between gonadotropin-releasing hormone 
agonists and increased cardiovascular-related toxicity.8 
Finally, it is worth mentioning that ADT may prolong the 
QT interval, as reported by Garnick et al after reviewing 
the results of three Phase III randomized trials of differ-
ent modalities of ADT. Indeed a prolonged QT interval 
(.450–500 msec) is associated with a higher incidence of 
arrhythmias and sudden death. ADT was associated with 
9–21 msec increases in the corrected QT interval among 
a total of 476 patients.13
Table  1  Potential  side  effects  experienced  by  men  receiving 
androgen deprivation therapy for prostate cancer
Hot flushes
Fatigue
erectile dysfunction/decreased libido
Reduced bone mass and skeletal complications
Metabolic complications
increased fat mass/weight gain
Cardiovascular complications
Anemia
Reduced muscle strength/fatigue
Cognitive changes/depression
Table 2 Definition of metabolic syndrome in men
Any three or more of the following criteria:
• Waist circumference .102 cm
• Triglycerides $150 mg/100 mL
• High-density lipoprotein cholesterol ,40 mg/100 mL
• Blood pressure $130/85 mmHg
• Fasting glucose $110 mg/100 mL
Note: *According to the National Cholesterol education Program’s Adult Treatment 
Panel iii.
Table 3 Classical metabolic syndrome changes and metabolic 
changes  in  men  treated  with  gonadotropin-releasing  hormone 
agonists
Classical  
metabolic 
syndrome
Men treated with 
gonadotropin-releasing 
hormone agonists
Blood pressure increased No change
Waist circumference increased increased
Waist-to-hip ratio increased No change
Triglycerides increased increased
High-density lipoprotein 
cholesterol
Decreased increased
Fat accumulation Visceral subcutaneous
Adiponectin Decreased increasedCancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Effect on cardiovascular events  
and mortality
Although there is much evidence confirming a profound 
effect of ADT on metabolic changes, the real impact of the 
rate of cardiovascular events and cardiovascular morbidity 
is far from clear. Several large cohort studies have examined 
the association between ADT and increased incidence of 
cardiovascular disease and diabetes. In a recent population-
based observational study of 37,443 men of all ages with 
nonmetastatic prostate cancer, using data from the Veterans 
Administration, Keating et al reported an association between 
gonadotropin-releasing hormone agonists and a significantly 
increased risk of incident diabetes (adjusted hazards ratio 
[HR] = 1.28, 95% confidence interval [CI]: 1.19–1.38), 
incident coronary heart disease (adjusted HR = 1.19, 95% 
CI: 1.10–1.28), myocardial infarction (adjusted HR = 1.28, 
95% CI: 1.08–1.52), sudden death (adjusted HR = 1.35, 95% 
CI:1.18–1.54), and stroke (adjusted HR = 1.22, 95% CI: 1.10–
1.36). Combined androgen blockade is significantly associ-
ated with an increased risk of incident coronary heart disease 
(adjusted HR = 1.27, 95% CI: 1.05–1.53) and orchiectomy is 
associated with coronary heart disease (adjusted HR = 1.40, 
95% CI: 1.04–1.87) and myocardial infarction (adjusted 
HR = 2.11, 95% CI: 1.27–3.50). The same study concluded 
that monotherapy with nonsteroidal antiandrogen was not 
associated with any of the toxic effects examined, therefore 
suggesting a potentially wider place in patients with cardio-
vascular toxicity. Incident coronary heart disease was defined 
as coronary heart disease identified at least 6 months after 
diagnosis in men without prevalent disease.14 These findings 
have been confirmed in another study from the same group 
using the Surveillance, Epidemiology and End Results 
(SEER) Medicare data (n = 73,196), but analyses were   limited 
to older men ($66 years), and information was lacking 
about antiandrogens and whether ADT was associated with 
stroke. Gonadotropin-releasing hormone agonist use was 
associated with increased risk of incident diabetes (adjusted 
HR = 1.44, P , 0.001), coronary heart disease (adjusted 
HR = 1.16, P , 0.001), myocardial infarction (adjusted 
HR = 1.11, P = 0.03), and sudden cardiac death (adjusted 
HR = 1.16, P = 0.004).15 Saigal et al   examined the risk of 
cardiovascular morbidity in men $65 years with newly diag-
nosed prostate cancer on ADT also using the SEER Medicare 
data (n = 22,816). They found that men who received ADT 
had a 20% higher risk of cardiovascular morbidity compared 
with a matched male population that did not receive ADT 
(adjusted HR = 1.20, 95% CI: 1.15–1.26; P , 0.05). This 
increased risk was observed within the initial 12 months 
of ADT.16 A recent preliminary report from a population-
based, matched-cohort study found an association between 
continuous use of ADT for at least 6 months in older men 
($66 years) and increased incidence of diabetes (adjusted 
HR = 1.16, 95% CI: 1.11–1.21), but not of myocardial 
infarction or sudden cardiac death.17 Three retrospective 
cohort studies have reported a significantly increased risk 
of cardiovascular mortality from ADT (adjusted HR 1.16,15 
1.35,14 and 2.618). The studies by Keating et al have been 
described previously.14,15 The study by Tsai et al reported 
analyses of 4892 men included in the CAPSURE (Cancer 
of the Prostatic Urologic Research Endeavor) database. The 
authors suggested the association of ADT with an increased 
risk of cardiovascular mortality in a subset of men under-
going radical prostatectomy for localized prostate cancer 
(adjusted HR = 2.6, 95% CI: 1.4–4.7; P = 0.002) but not 
in a subset of men treated with radiation therapy.18 The risk 
of severe cardiovascular morbidity after ADT is not equal 
across the population. Patients aged above 65 years have 
a higher risk than younger men.18 The 5-year cumulative 
incidence of cardiovascular mortality was 5.5% for patients 
aged $65 years who received ADT and 2% for non-ADT 
controls. For younger patients, the 5-year cumulative inci-
dence of cardiovascular mortality was 3.6% for those who 
received ADT and 2% in those not treated with ADT.18 Nanda 
et al reported the results of a retrospective study including 
5077 men with localized or locally advanced prostate can-
cer who were treated with or without a median of 4 months 
of neoadjuvant hormone therapy (gonadotropin-releasing 
hormone agonist and antiandrogen) followed by radiation 
therapy. They found that the use of neoadjuvant hormone 
therapy is significantly associated with an increased risk of 
all-cause mortality among men with a history of coronary 
artery disease-induced congestive heart failure or myocar-
dial infarction, but not among men with no comorbidity 
or a single risk factor for coronary artery disease. In the 
subgroup of patients with coronary artery disease-induced 
congestive heart failure or myocardial infarction, 25/95 
deaths were reported in ADT-treated patients (26.3%) and 
18/161 deaths in non-ADT-treated controls (11.2%, adjusted 
HR = 1.96, 95% CI: 1.04–3.71, P = 0.04).19 D’Amico et al 
analyzed post hoc pooled data on 1372 patients from three 
randomized trials of radiation therapy with or without ADT 
for localized prostate cancer. They found a shorter time to 
fatal myocardial infarction in men aged $65 years who 
received 6 months of ADT compared with men in this age 
group with no ADT use (P = 0.017). Additional evidence to 
support this result is needed.20Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Interestingly, the results of these large epidemiological 
surveys are not supported by secondary analysis of cardiovas-
cular events and mortality observed in prospective random-
ized trials evaluating the benefit of early hormone therapy, 
especially in combination with external beam radiation 
therapy. Secondary analyses of four randomized controlled 
studies from the Radiation Therapy Oncology Group or 
  European Organization for Research and   Treatment of Cancer 
(EORTC) have found no association between neoadjuvant 
or adjuvant ADT and cardiovascular-related mortality 
(Table 4).21–24 It has to be noted that none of these studies 
were primarily designed to assess cardiovascular mortality. 
A recently completed EORTC randomized study (Protocol 
22961) comparing radiation therapy plus a total of 6 months 
ADT with radiation therapy plus a total of 3 years ADT in 
patients with locally advanced prostate cancer showed no 
significant difference in the incidence of fatal cardiac events 
at 5-year follow-up (4.0% versus 3.0%, respectively).25
Consequently, the physicians are left with that contro-
versy opposing the “epidemiologists” and the aficionados of 
randomized controlled trials. But, is it important to address 
that controversy? It is clear enough that ADT induces anthro-
pomorphic and metabolic changes that have been known for 
years to be associated with an increased cardiovascular risk. 
Why would it be different in prostate cancer patients receiving 
ADT? The more important conclusion is that physicians who 
prescribe ADT should be aware of these metabolic side 
effects, and monitor and treat them according to standard 
recommendations, as any primary care physician would do 
for any man concerned about his health. And even more 
important, it should remind the physician that ADT is not an 
innocuous treatment, and that it should be prescribed only in 
men needing ADT. The US Food and Drug   Administration 
is examining the safety of gonadotropin-releasing hormone 
agonists for treatment of prostate cancer, and believes it is 
important to inform patients and health care professionals 
about these side effects.
In a recently published population-based study by 
Hemelrijck et al, 30,642 patients with prostate cancer 
received primary hormonal treatment, 26,432 received 
  curative treatment, and 19,527 had surveillance. Increased 
relative risks of nonfatal and fatal cardiovascular disease were 
found among all men with prostate cancer, especially those 
treated with hormonal treatment. They concluded that cardio-
vascular disease risk should be considered when prescribing 
hormonal treatment, but should not be a contraindication 
when the expected benefit is real.26 This supports the recent 
science advisory from the American Heart Association, the 
American Cancer Society, and the American Urological 
Association.27
Follow-up and management  
of patients on ADT
The side effects of ADT should be explained to patients and 
communicated to the patient’s other physicians, including 
the primary care doctor. Physicians should be particularly 
attentive to identify men with cardiovascular comorbidity 
and those already with significant risk factors.
Prior to initiation of ADT, it is advisable that patients 
are screened by their primary care physician for   pre-  existing 
presence of metabolic syndrome and risk factors for 
  cardiovascular toxicity.27 This especially applies to older 
men (.65 years) who have a higher prevalence of comor-
bidities than younger men. Good medical care dictates that 
Table 4 Studies with rates of cardiovascular mortality not significantly different between treatment groups
Study Study population Treatment groups Number of cardiovascular 
deaths (P value)
eORTC 3089121 Locally advanced or node- 
positive prostate cancer not 
suitable for local treatment
immediate ADT 
vs deferred ADT
185  
(17.9%–19.7%)
RTOG 861022 Locally advanced prostate cancer RT + ADT (4 months) 
vs RT alone
57 
(14%–11%, P = 0.32)
RTOG 920223 Locally advanced prostate cancer RT + ADT (28 months) 
vs RT + ADT (4 months)
185 
(5.9%–4.8%, P = 0.58)
RTOG 853124 Locally advanced or node- 
positive prostate cancer 
(unfavorable prognosis)
RT+ indefinite ADT  
vs RT + salvage ADT for 
recurrence
117 
(8.4%–11.4%, P = 0.17)
eORTC 2296125 Locally advanced prostate cancer RT + ADT (6 months) 
vs RT + ADT (3 years)
31–25 
(4.0%–3.0%)
Abbreviations: ADT, androgen-deprivation therapy; RT, radiation therapy.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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prior to initiation of ADT, physicians collect abdominal 
perimeter and blood pressure, and measure fasting glu-
cose, low-density and high-density lipoprotein cholesterol, 
triglycerides, and ultrasensitive C-reactive protein. These 
tests are best repeated every 3 months during the first year 
of ADT because the treatment-related metabolic and body 
composition changes tend to arise within months of starting 
ADT.7,15,28 Body composition can be monitored simply using 
a bioimpedance balance. There are currently no optimal 
strategies to prevent or manage ADT-associated metabolic 
effects, other than existing recommendations to reduce the 
risk of diabetes and cardiovascular disease in the general 
population. Patients are encouraged to adopt a healthy 
lifestyle, such as a low-fat diet, regular physical exercise, 
smoking cessation, and moderate alcohol intake.28 Pharma-
cological options are considered if lifestyle modifications 
prove unsuccessful. Conditions like diabetes, hyperlipi-
demia, and hypertension should be managed. Patients with 
cardiovascular disease should receive appropriate preventive 
therapies if necessary, including lipid-lowering, antihyper-
tensive, glucose-lowering, and antiplatelet therapies.27 The 
preventive role of statins, other cardioprotective agents 
(eg, aspirin, beta-blockers), and insulin sensitizers should 
be studied in men receiving ADT for prostate cancer. Tore-
mifene, a second-generation selective receptor modulator, 
has shown promise for the management of ADT-associated 
lipid changes, but its effect on cardiovascular outcomes has 
not yet been evaluated.
Recent studies have highlighted the growing role of 
  supervised resistance and aerobic exercise programs to 
counteract the metabolic impact of sarcopenic obesity and 
peripheral insulin resistance. Segal et al demonstrated that 
a 12-week resistance exercise intervention (three times/
week) reduced fatigue (P = 0.002), improved health-related 
quality of life (P = 0.001), and increased levels of upper body 
(P = 0.009) and lower body (P , 0.001) muscular fitness in 
men with prostate cancer receiving ADT. The intervention 
group included 82 men, while the control group included 
73 men on a waiting list to undergo the same course of 
physical therapy.29 These findings were supported by a study 
conducted by Galvao et al who examined the effects of   
longer progressive resistance training (20 weeks) at a reha-
bilitation clinic in 10 men on ADT for localized prostate 
cancer. Beneficial effects were increased muscle strength 
(upper and lower body) and endurance (P , 0.001).30 In both 
of the aforementioned studies, resistance training increased 
muscle thickness and preserved whole body lean mass, with 
no change in fat mass. Levels of prostate serum antigen and 
testosterone remained unchanged, indicating that resistance 
training can be safely tolerated in men receiving ADT.30,31 
Segal et al recently demonstrated in a randomized controlled 
study that resistance and aerobic exercise alleviate fatigue 
in men with prostate cancer receiving radiation therapy with 
or without ADT. Resistance exercise generated longer-term 
improvements and additional benefits for quality of life, 
strength, triglycerides, and body fat.32 Although there are 
no results as yet from large randomized controlled studies 
of ADT-treated patients with prostate cancer assessing the 
impact of exercise on cardiovascular and metabolic compli-
cations, physical training in other cancer patients, as well as 
in healthy adults, has been found to reduce cardiovascular 
and metabolic diseases significantly. Two large studies in this 
context are under way.
One might be tempted to believe that the cardiovascular 
side effects of ADT could be reduced with intermittent ADT 
(intermittent androgen deprivation) use when compared with 
continuous administration of gonadotropin-releasing hormone 
agonists. Several trials indicated that short-term side effects, 
such as sexual function and quality of life, are improved 
during the off-treatment period, when the administration 
of the luteinizing hormone releasing   hormone agonist is 
  suspended.33 Whether intermittent androgen deprivation also 
alleviates long-term side effects is far more controversial. 
None of the prospective randomized trials evaluating ADT 
has indeed investigated the side effects of ADT. In addition, it 
is noteworthy that, according to d’Amico et al,   cardiovascular 
toxicity raised already after 6 months of ADT, and that not all 
patients will recover a normal testosterone when interrupting 
the administration of the luteinizing hormone releasing 
hormone agonist.34,35 This is important because, in contrast 
with the anticancer effect that requires profound suppression 
of testosterone, an increased cardiovascular risk is already 
observed in cases of mild hypogonadism.36
In conclusion, there are still insufficient data to determine 
whether intermittent ADT has the potential to prevent or 
reverse the long-term complications associated with ADT, 
and this strategy should not be offered as an alternative in 
men requiring ADT and at high risk of cardiovascular   disease. 
In nonmetastatic prostate cancer patients, nonsteroidal 
antiandrogen monotherapy offers an important advantage 
  compared with luteinizing hormone releasing hormone 
agonists. It indeed increases circulating testosterone, and 
therefore causes fewer changes in body weight, body mass 
index, and percentage of fat mass and lean mass.37Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Conclusion
At this time, there is a growing body of evidence to 
  suggest that ADT induces change in body composition 
and   dyslipidemia. It is plausible that ADT could increase 
cardiovascular risk because of the adverse effect of ADT on 
risk factors for cardiovascular disease. It is advisable that 
before initiation and during ADT treatment, men with   prostate 
cancer are periodically checked for potential metabolic effects 
by their physician. A healthy lifestyle, including a balanced 
diet and regular physical activity, should be encouraged. 
Patients with known cardiovascular disease should receive 
appropriate preventive treatment if necessary, including lipid-
lowering, antihypertensive, glucose-lowering, and antiplatelet 
therapies. ADT should not be unnecessarily administered 
to prostate cancer patients with pre-existing cardiovascular 
disease, and certainly not to those in whom the risk of prostate 
cancer-specific mortality is low. In the decision about whether 
to initiate ADT or not, the physician treating the patient for 
prostate cancer should carefully weigh the potential benefits 
of ADT against the possible risks in the individual patient. 
There is a need for large prospective studies to investigate 
the metabolic and cardiovascular effects of ADT, and to 
identify populations of men at highest risk of developing 
these side effects, such as diabetics. The benefit/risk ratio 
of ADT should also be assessed in younger patients and 
in those with earlier-stage prostate cancer and a favorable 
prognosis. Further research should focus on the development 
of strategies to prevent or reverse the cardiovascular and 
metabolic toxicities associated with ADT.
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